{"id":156913,"date":"2025-08-18T23:13:10","date_gmt":"2025-08-18T23:13:10","guid":{"rendered":"https:\/\/www.europesays.com\/us\/156913\/"},"modified":"2025-08-18T23:13:10","modified_gmt":"2025-08-18T23:13:10","slug":"fda-approves-ketamine-product-for-surgical-pain-management","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/156913\/","title":{"rendered":"FDA approves ketamine product for surgical pain management"},"content":{"rendered":"<p class=\"mb-4 text-lg md:leading-8 break-words\">The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Ketamine is the only psychedelic or psychedelic-adjacent drug on the World Health Organization Essential Medicines List, with its global market projected to grow from $750 million to $3.42 billion by 2034.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">PharmaTher, which developed KETARx, believes there is a promising outlook for the ketamine market and that the FDA approval provides a strong foundation for expanding the development of ketamine across diverse therapeutic areas. These areas include depression, neurological disorders (Parkinson disease, amyotrophic lateral sclerosis), and rare or chronic pain conditions.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">&#8220;Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for PharmaTher is a testament to years of dedicated development, signaling a new era of growth,&#8221; Fabio Chianelli, founder and CEO of PharmaTher, said in a statement. &#8220;We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders.&#8221;<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Approval of KETARx was granted to PharmaTher.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\"><a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/11\/3130994\/0\/en\/PharmaTher-Announces-FDA-Approval-of-Ketamine-KETARx.html\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:More Information;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">More Information<\/a><\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Copyright \u00a9 2025 HealthDay. All rights reserved.<\/p>\n<p><img alt=\"\" loading=\"lazy\" width=\"71\" height=\"22\" decoding=\"async\" data-nimg=\"1\" class=\"rounded-lg\" style=\"color:transparent\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/08\/6cded3008b014d837d16c696f69f43ae.jpeg\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.&hellip;\n","protected":false},"author":3,"featured_media":156914,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[63205,6434,210,4579,1060,47788,4464,26122,91301,67,132,68],"class_list":["post-156913","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-amyotrophic-lateral-sclerosis","tag-food-and-drug-administration","tag-health","tag-ketamine","tag-medication","tag-neurological-disorders","tag-pain-management","tag-psychedelic","tag-therapeutic-areas","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115052308541476277","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/156913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=156913"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/156913\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/156914"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=156913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=156913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=156913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}